Abeona Therapeutics Announces Fast Track Designation from FDA for ABO-102 in Sanfilippo Syndrome Type A
October 25, 2016 07:45 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 25, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at Orphan Drugs & Rare Disease Conference, London UK
October 20, 2016 07:43 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 20, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO):ABO-102 gene therapy well-tolerated at low-dose Cohort of 3 subjects Significant average...
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-102 Gene Therapy in Sanfilippo Syndrome Type A
October 18, 2016 07:45 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY, and CLEVELAND, OH--(Marketwired - October 18, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical- stage biopharmaceutical company focused on developing gene therapies for...
Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
October 14, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 14, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for...
Abeona Therapeutics Announces Publication of Preclinical Data Supporting Clinical Translation of Juvenile Batten Disease Gene Therapy
October 07, 2016 09:19 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 07, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO):Preclinical efficacy data demonstrated corrected motor deficits, attenuated...
Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
October 05, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - October 05, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)ABO-102 (AAV-SGSH) delivers first-in-man AAV-based gene therapy administered by single...
Abeona Therapeutics to Present at Jefferies Gene Editing & Gene Therapy Summit
October 04, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH --(Marketwired - October 04, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa
September 29, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 29, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...
Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
September 26, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts)...
Abeona Therapeutics to Present at Ladenburg Thalmann 2016 Healthcare Conference
September 23, 2016 07:03 ET
|
Abeona Therapeutics Inc.
NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 23, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on developing therapies for...